About this medicine
Product information is provided to support understanding and conversations with your care team. Follow the approved leaflet and your prescriber’s instructions.
Content migrated from the company website; pending clinical review before final publication.
Dosage forms
Oral tablets (40 and 80 mg)
Drug class
Tyrosine kinase inhibitor; third-generation EGFR growth-factor inhibitor
Administration
Take once daily, with or without food. If swallowing the tablet is difficult, the tablet may be dissolved in 60 mL of water and taken immediately.
Uses
• First-line treatment, as monotherapy or in combination with chemotherapy, and adjuvant treatment of non-small cell lung cancer (NSCLC) with EGFR mutations, exon 19 deletions or the exon 21 L858R mutation
• EGFR-mutated adenocarcinoma-type non-small cell lung cancer (NSCLC) with leptomeningeal metastases
Competitive advantages
Osimertinib is effective in patients with mutations associated with resistance to earlier treatments such as erlotinib and gefitinib. Its ability to inhibit EGFR mutations including T790M, exon 19 deletions and L858R, together with its ability to cross the blood–brain barrier, plays an important role in treating brain metastases and controlling advanced non-small cell lung cancer (NSCLC).
This medicine is recognized as a first-line treatment choice for patients with EGFR mutations and provides long-term outcomes with high effectiveness and a better safety profile than earlier generations. Osimertinib is effective alone or with chemotherapy such as pemetrexed and platinum-based medicines, and has a role in controlling drug resistance, making it a gold-standard lung cancer treatment.
Original company product page ↗